Live: Will Keysight Technologies Fall After Tonight’s Q3 Earnings? Shares Are Down 7% Today

Investing

Regeneron : REGN

All Regeneron Articles

248 Articles

Lee Jackson | Jan 12, 2017 at 10:05 AM EST

Merrill Lynch’s 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential

Chasing stocks in an overbought market is dangerous. With that in mind, overbought markets can go higher. These stocks hold…

Chris Lange | Jan 6, 2017 at 11:55 AM EST

Friday’s 6 Biopharma Movers That Can’t Be Ignored

2017 could be different for the health care sector. It is very possible that this new administration could lead to…

Jon C. Ogg | Dec 20, 2016 at 10:05 AM EST

Key Analyst Upgrades and Downgrades for Tuesday: Alcoa, Arch Coal, Baidu, Ciena, JD.com, Vale and Many More

Companies receiving analyst upgrades, downgrades, initiations or other key notes on Tuesday morning include Alcoa, Arch Coal, Baidu, Ciena, JD.com…

Lee Jackson | Dec 19, 2016 at 8:35 AM EST

Merrill Lynch Out With 11 Top Stock Ideas for 2017

Here are, the 11 top stock picks from the analysts at Merrill Lynch for 2017. Most look well-suited for growth…

Lee Jackson | Nov 11, 2016 at 9:35 AM EST

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there…

Chris Lange | Nov 4, 2016 at 10:05 AM EDT

Regeneron Investors Cheer Q3 Earnings Beat, Eylea Growth

Regeneron Pharmaceuticals reported mixed third-quarter financial results before the markets opened on Friday.

Chris Lange | Oct 13, 2016 at 9:05 AM EDT

Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration

Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into…

Lee Jackson | Sep 19, 2016 at 8:25 AM EDT

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four…

Jon C. Ogg | Aug 29, 2016 at 10:10 AM EDT

8 Top Movers and Hot Stocks for Monday

Stocks overall were fractionally higher early on Monday, August 29, 2016. That makes the big percentages gainers and losers and…

Jon C. Ogg | Aug 5, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: FireEye, Occidental Petroleum, SeaWorld, Teva Pharma, Windstream, Zynga and More

The top analyst upgrades, downgrades and initiations seen on Friday morning include FireEye, Occidental Petroleum, SeaWorld, Teva Pharmaceutical, Windstream and…

Lee Jackson | Aug 4, 2016 at 10:40 AM EDT

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that…

Paul Ausick | Jun 22, 2016 at 4:04 PM EDT

Verifone, Biogen Crash Wednesday’s 52-Week Low Club

June 22, 2016: Here are four stocks trading with relatively heavy volume among 40 equities making new 52-week lows in…

Jon C. Ogg | Apr 20, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo…

Chris Lange | Apr 1, 2016 at 9:50 AM EDT

Regeneron Rises on Positive Top-Line Results

Regeneron Pharmaceuticals has announced that two Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic…

Chris Lange | Mar 16, 2016 at 1:35 PM EDT

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol…

1 … 8 9 10 11 12 … 17

Regeneron : REGN

All Regeneron Articles

Merrill Lynch’s 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential

Friday’s 6 Biopharma Movers That Can’t Be Ignored

Key Analyst Upgrades and Downgrades for Tuesday: Alcoa, Arch Coal, Baidu, Ciena, JD.com, Vale and Many More

Merrill Lynch Out With 11 Top Stock Ideas for 2017

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

Regeneron Investors Cheer Q3 Earnings Beat, Eylea Growth

Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

8 Top Movers and Hot Stocks for Monday

Top Analyst Upgrades and Downgrades: FireEye, Occidental Petroleum, SeaWorld, Teva Pharma, Windstream, Zynga and More

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Verifone, Biogen Crash Wednesday’s 52-Week Low Club

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

Regeneron Rises on Positive Top-Line Results

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Live: Will Keysight Technologies Fall After Tonight’s Q3 Earnings? Shares Are Down 7% Today

Live: Will Jack Henry Crush Q4 Earnings Tonight After the Market Closes?

At 55 With No Dividend Income, $1,500 a Month Into the SCHD ETF Is the Last Lever You Have

Serve Robotics Sinks 7% as Guidance Cut Overshadows Grubhub Deal; Symbotic Drops 5%, DoorDash Ticks Up

United Microelectronics Falls 7%, Tower Semiconductor Sinks 10%, GlobalFoundries Drops 7% as AI Spending Fears Hit Foundries

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

At 63, His Sick-Pay Checks Kept Coming. After Six Months, Social Security Tax Stopped.

Most of the SPYI ETF’s 12% Payout Is Your Own Money Coming Back. The IRS Waits Until You Sell.

At 55 With No Dividend Income, $1,500 a Month Into the SCHD ETF Is the Last Lever You Have

Regeneron : REGN

All Regeneron Articles

Merrill Lynch’s 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential

Friday’s 6 Biopharma Movers That Can’t Be Ignored

Key Analyst Upgrades and Downgrades for Tuesday: Alcoa, Arch Coal, Baidu, Ciena, JD.com, Vale and Many More

Merrill Lynch Out With 11 Top Stock Ideas for 2017

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

Regeneron Investors Cheer Q3 Earnings Beat, Eylea Growth

Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

8 Top Movers and Hot Stocks for Monday

Top Analyst Upgrades and Downgrades: FireEye, Occidental Petroleum, SeaWorld, Teva Pharma, Windstream, Zynga and More

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Verifone, Biogen Crash Wednesday’s 52-Week Low Club

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

Regeneron Rises on Positive Top-Line Results

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Live: Will Keysight Technologies Fall After Tonight’s Q3 Earnings? Shares Are Down 7% Today

Live: Will Jack Henry Crush Q4 Earnings Tonight After the Market Closes?

At 55 With No Dividend Income, $1,500 a Month Into the SCHD ETF Is the Last Lever You Have

Serve Robotics Sinks 7% as Guidance Cut Overshadows Grubhub Deal; Symbotic Drops 5%, DoorDash Ticks Up

United Microelectronics Falls 7%, Tower Semiconductor Sinks 10%, GlobalFoundries Drops 7% as AI Spending Fears Hit Foundries

Featured Reads

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

At 63, His Sick-Pay Checks Kept Coming. After Six Months, Social Security Tax Stopped.